Adcock Ingram Holdings Limited - Asset Resilience Ratio
Adcock Ingram Holdings Limited (AIP) has an Asset Resilience Ratio of 0.16% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AIP strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Adcock Ingram Holdings Limited's Asset Resilience Ratio has changed over time. See AIP equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Adcock Ingram Holdings Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adcock Ingram Holdings Limited (AIP) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ZAC0.00 | 0% |
| Short-term Investments | ZAC13.39 Million | 0.16% |
| Total Liquid Assets | ZAC13.39 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Adcock Ingram Holdings Limited maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Adcock Ingram Holdings Limited Industry Peers by Asset Resilience Ratio
Compare Adcock Ingram Holdings Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Adcock Ingram Holdings Limited (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Adcock Ingram Holdings Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.16% | ZAC13.39 Million ≈ $7.12K |
ZAC8.35 Billion ≈ $4.44 Million |
+0.36pp |
| 2023-06-30 | -0.20% | ZAC-16.83 Million ≈ $-8.94K |
ZAC8.26 Billion ≈ $4.39 Million |
-4.29pp |
| 2022-06-30 | 4.08% | ZAC322.14 Million ≈ $171.20K |
ZAC7.89 Billion ≈ $4.19 Million |
+3.34pp |
| 2021-06-30 | 0.74% | ZAC52.32 Million ≈ $27.80K |
ZAC7.04 Billion ≈ $3.74 Million |
-3.07pp |
| 2020-06-30 | 3.82% | ZAC274.10 Million ≈ $145.67K |
ZAC7.18 Billion ≈ $3.82 Million |
-3.35pp |
| 2019-06-30 | 7.17% | ZAC448.25 Million ≈ $238.22K |
ZAC6.25 Billion ≈ $3.32 Million |
+0.72pp |
| 2018-06-30 | 6.45% | ZAC404.63 Million ≈ $215.04K |
ZAC6.27 Billion ≈ $3.33 Million |
-4.19pp |
| 2017-06-30 | 10.64% | ZAC592.07 Million ≈ $314.65K |
ZAC5.56 Billion ≈ $2.96 Million |
+10.60pp |
| 2013-06-30 | 0.04% | ZAC2.73 Million ≈ $1.45K |
ZAC6.82 Billion ≈ $3.62 Million |
-- |
About Adcock Ingram Holdings Limited
Adcock Ingram Holdings Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of healthcare products to private and public sectors in Southern Africa and India. It operates through four segments: Consumer, Over the Counter (OTC), Prescription, and Hospital Products and Services. The company provides various healthcare, personal care, and homecare products… Read more